We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
COLO-B.CO

Price
797.20
Stock movement up
+6.80 (0.86%)
Company name
Coloplast A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Medical Instruments & Supplies
Markedsverdi
165.29B
Ent verdi
194.63B
Pris/omsetning
6.12
Pris/bok
9.21
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
320.65%
Etterfølgende P/E
32.72
Fremtidig P/E
29.24
PEG
-
EPS-vekst
4.33%
1 års avkastning
4.26%
3 års avkastning
-9.92%
5 års avkastning
0.53%
10 års avkastning
4.44%
Sist oppdatert: 2024-12-21

UTBYTTE

COLO-B.CO betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E32.72
Pris til OCF59.76
Pris til FCF112.29
Pris til EBITDA37.96
EV i forhold til EBITDA44.70

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning6.12
Pris til bok9.21
EV i forhold til salg7.20

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall207.34M
EPS (TTM)22.45
FCF per aksje (TTM)6.54

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)27.03B
Bruttofortjeneste (TTM)18.27B
Driftsinntekter (TTM)7.37B
Netto inntekt (TTM)5.05B
EPS (TTM)22.45
EPS (1 år fremover)27.26

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)67.59%
Driftsmargin (TTM)27.25%
Fortjenestemargin (TTM)18.69%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter788.00M
Netto fordringer4.67B
Samlede omløpsmidler10.44B
Goodwill19.38B
Immaterielle eiendeler10.96B
Eiendom, anlegg og utstyr13.27B
Sum eiendeler48.07B
Leverandørgjeld1.52B
Kortsiktig/nåværende langsiktig gjeld22.63B
Sum kortsiktig gjeld10.20B
Sum gjeld30.13B
Aksjonærenes egenkapital17.94B
Netto varige driftsmidler0.00

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)2.77B
Kapitalutgifter (TTM)1.29B
Fri kontantstrøm (TTM)1.47B
Utbetalt utbytte (TTM)4.72B

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning28.16%
Avkastning på eiendeler10.51%
Avkastning på investert kapital12.60%
Kontantavkastning på investert kapital3.67%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning791.60
Daglig høy799.20
Daglig lav786.60
Daglig volum333K
Tidenes høyeste1182.50
1 år analytikerestimat926.10
Beta0.34
EPS (TTM)22.45
Utbytte per aksje-
Ex-div dato6 Dec 2024
Neste dato for resultatpresentasjon4 Feb 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
COLO-B.COS&P500
Nåværende prisfall fra toppnotering-32.58%-2.74%
Høyeste prisfall-43.67%-56.47%
Dato for høyeste fall28 Oct 19949 Mar 2009
Gj.snittlig fall fra topp-11.73%-11.13%
Gj.snittlig tid til ny topp16 days12 days
Maks tid til ny topp854 days1805 days
SELSKAPSOPPLYSNINGER
COLO-B.CO (Coloplast A/S) company logo
Markedsverdi
165.29B
Markedsverdi kategori
Large-cap
Beskrivelse
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Ansatte
16639
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
Denmark
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved.Distribution of ye...
5. desember 2024
The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted t...
4. desember 2024
On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based produc...
14. november 2024
The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk...
12. november 2024
Coloplast AS (CLPBF) reports robust financial performance with 8% organic growth and strategic product launches, despite facing supply disruptions and competitive pressures.
6. november 2024
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million. Organic growth rates b...
5. november 2024
2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraord...
5. november 2024
Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect. “We have entered the final year of...
5. november 2024
Earnings preview of key companies reporting this week and what to look out for.
1. november 2024
Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial...
21. oktober 2024
Neste side